Title |
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
|
---|---|
Published in |
BMC Hematology, July 2015
|
DOI | 10.1186/s12878-015-0029-1 |
Pubmed ID | |
Authors |
Róbert Pálmason, Ola Lindén, Johan Richter |
Abstract |
Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib. We report a case of a 57 year old female with post-polycythemic myelofibrosis who was treated with Ruxolitinib. Approximately 9 weeks later she presented with a rapidly fatal, suspected EBV driven lymphoproliferative disorder in the CNS. Our report further underlines that patients treated with Ruxolitinib should be monitored closely for reactivations of opportunistic pathogens and viral infections. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Saudi Arabia | 1 | 33% |
United States | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 16 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 4 | 25% |
Researcher | 3 | 19% |
Student > Master | 1 | 6% |
Student > Doctoral Student | 1 | 6% |
Professor > Associate Professor | 1 | 6% |
Other | 1 | 6% |
Unknown | 5 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 31% |
Business, Management and Accounting | 2 | 13% |
Immunology and Microbiology | 2 | 13% |
Nursing and Health Professions | 1 | 6% |
Arts and Humanities | 1 | 6% |
Other | 1 | 6% |
Unknown | 4 | 25% |